Cystic echinococcosis in Southern Israel

2016 ◽  
Vol 61 (1) ◽  
Author(s):  
Shalom Ben-Shimol ◽  
Orli Sagi ◽  
Ohad Houri ◽  
Elina Bazarsky ◽  
Anat Berkowitz ◽  
...  

AbstractThe aim of this retrospective, population-based study was to characterize demographically and clinically cystic-echinococcosis (CE) in southern Israel, between 2005 and 2012. Newly-diagnosed (nd-CE) and past-diagnosed (pd-CE, diagnosed before the study) cases were defined. Two populations live in southern-Israel, receiving medical treatment at a single hospital: the Jewish and the Bedouin populations (resembling resource-rich and resource-poor populations, respectively). 126 CE cases were identified; 55 nd-CE and 71 pd-CE. Mean annual nd-CE incidence per 100,000 in the Bedouin and Jewish populations were 2.7 ± 1.2 and 0.4 ± 0.3, respectively (P<0.001). None of the Bedouin and 86.5% of the Jewish patients were born outside Israel. Liver and lung involvement were recorded in 85.7% and 15.1% of overall-CE, respectively. Abdominal pain, cough, fever, eosinophilia and asymptomatic disease were documented in 63.6%, 32.7%, 27.3%, 41.5% and 12.7% of nd-CE, respectively. Serology sensitivity for first test and any positive test were 67.3% and 83.3%, respectively. Computed tomography, ultrasonography and X-ray diagnosis were documented in 79.2%, 58.4% and 17.0% of overall-CE, respectively, with ultrasonography mainly used in liver-CE and X-ray in lung-CE. Treatment included surgery and albendazole in 50.0% and 55.3% of CE, respectively. We conclude that CE is endemic in southern-Israel among the Bedouin population, while disease is probably mainly imported in the Jewish population. Liver involvement and eosinophilia rates were high compared with those of other endemic regions, possibly due to differences in the timing of diagnosis. These findings may help developing treatment and prevention strategies.

2021 ◽  
Author(s):  
Khalid Orayj ◽  
Tahani Almeleebia ◽  
Easwaran Vigneshwaran ◽  
Sultan Alshahrani ◽  
Sirajudeen. S. Alavudeen ◽  
...  

2006 ◽  
Vol 64 (4) ◽  
pp. 450-455 ◽  
Author(s):  
Johannes L. P. Kuijpens ◽  
Maryska L. G. Janssen-Heijnen ◽  
Valery E. P. P. Lemmens ◽  
Harm R. Haak ◽  
A. Caroline Heijckmann ◽  
...  

2021 ◽  
Author(s):  
Sadaf G. Sepanlou ◽  
Farid Najafi ◽  
Hossein Poustchi ◽  
Mahboubeh Parsaeian ◽  
Ali Ahmadi ◽  
...  

Abstract In this cross-sectional population-based study, we used the baseline data of the Prospective Epidemiologic Research Studies in IrAN (PERSIAN) cohort study collected in Iran from 2014 to 2020. The main outcomes were the prevalence of hypertension and proportion of awareness, treatment, and control based on the 2017 ACC/AHA guideline compared to the seventh report of the Joint National Committee (JNC7). Of the total of 163770 participants, aged 35 to 70 years, 55.2% were female. The sex-age standardized prevalence of hypertension was 22.3% (95% CI: 20.6-24.1) based on the JNC7 guideline and 36.5% (31.1-41.8) based on the ACC/AHA guideline. A total of 24312 participants [14.1% [10.1, 18.1)] were newly diagnosed based on the ACC/AHA guideline. Compared to adults diagnosed with hypertension based on the JNC7 guideline, the newly diagnosed participants were mainly young literate males who had low levels of risk factors and were free from conventional comorbidities of hypertension. About 30.7% (25.9, 35.4) of them (4.3% of the entire population) were eligible for pharmacologic intervention based on the ACC/AHA guideline. Implementation of the new guideline may impose additional burden on health systems. However, early detection and management of elevated blood pressure may reduce the ultimate burden of hypertension in Iran.


2018 ◽  
Vol 9 (24) ◽  
pp. 4706-4711 ◽  
Author(s):  
Chao Zhang ◽  
Lele Liu ◽  
Fang Tao ◽  
Xu Guo ◽  
Guowei Feng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document